Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures
- PMID: 15570403
- DOI: 10.1007/s00223-004-0074-4
Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures
Abstract
RANKL (receptor activator of NF-kappaB) is a potent physiological inducer of osteoclastogenesis. Its actions are blocked by the decoy receptor osteoprotegerin (OPG), and treatment with OPG blocks bone resorption in postmenopausal women. Both positive and negative associations between serum OPG and bone mineral density (BMD) have been reported in the literature. We hypothesized that decreased OPG production relative to RANKL within bone itself could lead to increased risk of osteoporotic fracture. We included ten women with hip fracture (age 76.3 +/- 8.0 years, N.S, : hip BMD 0.686 +/- 1.3 g/cm2, P < 0.05) and 24 women with osteoarthrosis of the hip (age 72.8 +/- 7.2 years, hip BMD 0.832 +/- 1.1 g/cm(2)). Transiliac biopsies were obtained at the time of surgery. Total RNA was extracted from biopsies and reverse-transcribed. Real-time quantification of mRNA was performed with a SYBR Green I real time PCR assay, calculating relative gene expression with normalization of results for beta actin mRNA. Actin normalized mRNA levels for OPG and interleukin (IL)-6 were significantly lower in fracture patients, with a significantly higher RANKL/OPG ratio in patients with fractures. There was no significant difference in tumor necrosis factor (TNF), IL-1, IL-1ra, or IL-7 expression. IL-6 mRNA levels were lower in fracture patients (P < 0.05). The effect of increased RANKL/OPG ratio (Z = 2.08, P < 0.05) on fracture risk was additive to that of hip BMD T score (Z = -1.95, P < 0.05) when assessed using logistic regression. Elderly women with hip fractures exhibit an increased RANKL/OPG mRNA content of iliac bone. This is associated with increased fracture susceptibility, which is not in itself explained by low BMD.
Similar articles
-
Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.Bone. 2004 Jul;35(1):256-65. doi: 10.1016/j.bone.2004.03.012. Bone. 2004. PMID: 15207766
-
Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck.Bone. 2004 Jul;35(1):334-42. doi: 10.1016/j.bone.2004.02.006. Bone. 2004. PMID: 15207775
-
Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.Steroids. 2005 Dec 1;70(13):847-55. doi: 10.1016/j.steroids.2005.04.011. Epub 2005 Jul 7. Steroids. 2005. PMID: 16005483 Clinical Trial.
-
Fracture risks and their mechanisms in atopic dermatitis, focusing on receptor activator of nuclear factor kappa-B ligand.Clin Exp Dermatol. 2023 Oct 25;48(11):1209-1213. doi: 10.1093/ced/llad220. Clin Exp Dermatol. 2023. PMID: 37379576 Review.
-
Hip fracture patients, a group of frail elderly people with low bone mineral density, muscle mass and IGF-I levels.Acta Physiol Scand. 1999 Dec;167(4):347-50. doi: 10.1046/j.1365-201x.1999.00626.x. Acta Physiol Scand. 1999. PMID: 10632638 Review.
Cited by
-
Circulatory Levels of RANKL, OPG, and Oxidative Stress Markers in Postmenopausal Women With Normal or Low Bone Mineral Density.Biomark Insights. 2019 Aug 19;14:1177271919843825. doi: 10.1177/1177271919843825. eCollection 2019. Biomark Insights. 2019. PMID: 31452599 Free PMC article.
-
Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL.Cancer Res. 2010 Nov 1;70(21):8329-38. doi: 10.1158/0008-5472.CAN-10-2179. Epub 2010 Oct 26. Cancer Res. 2010. PMID: 20978204 Free PMC article.
-
Propofol attenuates osteoclastogenesis by lowering RANKL/OPG ratio in mouse osteoblasts.Int J Med Sci. 2018 May 14;15(7):723-729. doi: 10.7150/ijms.22713. eCollection 2018. Int J Med Sci. 2018. PMID: 29910677 Free PMC article.
-
Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis.Drugs Aging. 2014 Jun;31(6):413-24. doi: 10.1007/s40266-014-0179-z. Drugs Aging. 2014. PMID: 24797286 Free PMC article. Review.
-
Neuroimmune expression in hip osteoarthritis: a systematic review.BMC Musculoskelet Disord. 2017 Sep 11;18(1):394. doi: 10.1186/s12891-017-1755-2. BMC Musculoskelet Disord. 2017. PMID: 28893229 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous